pepscience

Sleep & neuroscience · RESEARCH PROFILE

DSIP

A peptide investigated in sleep physiology and stress-related signaling.

2 specifications·26 source documents·Source updated Jul 13, 2026

Discuss DSIP on glp1chat

Join the forum to discuss research with other members.

Visit forum(opens in a new tab)

At a glance

DSIP is a peptide studied for possible effects on sleep and stress signals. Researchers have measured changes in sleep patterns, but its name does not mean it reliably puts people to sleep; the findings vary by study.

Sleep is controlled by several interacting brain systems, not one on-off switch. DSIP research asks whether this peptide changes sleep stages or stress responses under particular experimental conditions. Results have not been consistent across studies, so its name can be misleading. It is more useful to think of it as a sleep-signaling research subject than as a reliable sleeping medicine.

Potential benefits & side effects

Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.

Potential benefits & research findings

The source discusses sleep recordings and clinical observations. Study size, reproducibility and adverse-event reporting should guide interpretation of any potential benefit.[2][3][8]

Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.

Side effects & evidence limitations

Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of DSIP.

Source-reported adverse effects and cautions

  • Remarkably safe profile: animal studies found no lethal dose even at extremely high doses; human studies report only mild, transient side effects (occasional headache or nausea)[1][8].
  • Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

    • Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.

    Editorial responsibility
    Pep Science editorial desk
    Last independent review
    Not yet recorded
    Editorial standards & corrections

    SPECIFICATIONS & SOURCE SCHEDULES

    Explore a vial size

    Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.

    Showing 5 mg · 2 source tables

    Source-derived research information. Table phases retain the source’s actual duration; open-ended phases are not converted into a fixed eight-week course. Review the original study before interpreting a schedule.

    Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

    Week 1Week 2Week 3Weeks 4–8
    WeekDaily Dose (mcg)Units (per injection) (mL)
    Week 1100 mcg6 units (0.06 mL)
    Week 2150 mcg9 units (0.09 mL)
    Week 3200 mcg12 units (0.12 mL)
    Weeks 4–8250–300 mcg15–18 units (0.15–0.18 mL)

    Frequency: Inject once daily subcutaneously, typically in the evening before bedtime[19][20]. For ≤10-unit (≤0.10 mL) administrations (Weeks 1–2), consider 30- or 50-unit insulin syringes for improved readability.

    Advanced / Extended Approach

    Week 5Weeks 6–8+
    WeekDaily Dose (mcg)Units (per injection) (mL)
    Week 5350–400 mcg21–24 units (0.21–0.24 mL)
    Weeks 6–8+400–500 mcg24–30 units (0.24–0.30 mL)

    Note: Advanced dosing (beyond 300 mcg) is based on anecdotal experience; formal human studies have primarily used doses up to ~300 mcg daily[21]. Use the minimum effective dose and increase only if needed.

    Additional schedule context & duration

    Concise summary of the once-daily regimen.

    • Goal: Support healthy sleep architecture and stress modulation over time[17][18].
    • Schedule: Daily subcutaneous injections for 4–8 weeks (extend to 12 weeks if desired).
    • Dose Range: 100–300 mcg daily with gradual titration; advanced up to 500 mcg.
    • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
    • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

    Suggested daily titration approach.

    • Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
    • Target: 250–300 mcg daily by Weeks 4–8.
    • Frequency: Once per day (subcutaneous), typically before bedtime.
    • Cycle Length: 4–8 weeks; optional extension to 12 weeks with periodic breaks.
    • Timing: Evening administration preferred; rotate injection sites.

    Read this protocol on Pep Science → · View cited documents ↓

    Preparation

    Preparation and stability depend on the formulation, diluent, container and handling. The source-specific notes below apply to the selected record.
    Reconstitution Steps
    1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
    2. Inject slowly down the vial wall; avoid foaming.
    3. Gently swirl/roll until dissolved (do not shake).
    4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

    Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

    Storage Instructions

    Proper storage preserves peptide quality.

    • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[22].
    • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks and avoid freeze–thaw[23].
    • Allow vials to reach room temperature before opening to reduce condensation uptake.

    Injection Technique

    General subcutaneous guidance from clinical best-practice resources[12].

    • Clean the vial stopper and skin with alcohol; allow to dry.
    • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][26].
    • Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
    • Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy[26].

    Understanding reconstitution ↗Storage principles ↗

    Materials & quantity planning

    Source materials checklist · 5 mg

    Plan based on an 8–12 week daily protocol with gradual titration.

    • Peptide Vials (DSIP, 5 mg each):

      • 8 weeks at ~200 mcg/day avg ≈ 2–3 vials
      • 12 weeks at ~200 mcg/day avg ≈ 3–4 vials
      • 12 weeks at ~300 mcg/day avg ≈ 5–6 vials
    • Insulin Syringes (U-100):

      • Per week: 7 syringes (1/day)
      • 8 weeks: 56 syringes
      • 12 weeks: 84 syringes
    • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

      • 3 vials: 9 mL → 1 × 10 mL bottle
      • 5 vials: 15 mL → 2 × 10 mL bottles
      • 6 vials: 18 mL → 2 × 10 mL bottles
    • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

      • Per week: 14 swabs (2/day)
      • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
      • 12 weeks: 168 swabs → recommend 2 × 100-count boxes

    Calculate a phased quantity

    Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.

    Complete each phase to calculate totals.

    Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.

    FOLLOW THE EVIDENCE

    References & further reading

    Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.

    1. 01

      Source document

      European Journal of Anaesthesiology — Delta sleep-inducing peptide: discovery, structure, and pharmacological overview (opens in a new tab)

      journals.lww.com

      Back to overview ↑
    2. 02

      Research publication

      Neuroscience & Biobehavioral Reviews (PubMed) — Delta-sleep-inducing peptide (DSIP): a review of sleep-promoting and neuromodulatory effects (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    3. 03

      Research publication

      European Neurology (PubMed) — Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    4. 04

      Research publication

      European Neurology (PubMed) — DSIP in insomnia: timing and frequency of administration in clinical trials (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    5. 05

      Source document

      Tocris Bioscience — Stability and storage guidelines for research peptides (opens in a new tab)

      www.tocris.com

      Back to overview ↑
    6. 06

      Public health resource

      MedlinePlus (U.S. National Library of Medicine) — Subcutaneous (SQ) injections: technique, site selection, and procedure (opens in a new tab)

      medlineplus.gov

      Back to overview ↑
    7. 07

      Source document

      Frontiers in Pharmacology — DSIP fusion peptides crossing the blood-brain barrier and efficacy in insomnia models (opens in a new tab)

      www.frontiersin.org

      Back to overview ↑
    8. 08

      Research publication

      European Neurology (PubMed) — Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic pain episodes (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    9. 09

      Research publication

      European Neurology (PubMed) — DSIP in the treatment of withdrawal syndromes from alcohol and opiates (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    10. 10

      Source document

      Johns Hopkins Arthritis Center — How to give a subcutaneous injection: site rotation and best practices (opens in a new tab)

      www.hopkinsarthritis.org

      Back to overview ↑
    11. 11

      Research publication

      European Neurology (PubMed) — Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients (double-blind study) (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    12. 12

      Public health resource

      CDC — Vaccine administration: subcutaneous route (angle/site guidance) (opens in a new tab)

      www.cdc.gov

      Back to overview ↑
    13. 13

      Public health resource

      NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)

      www.ncbi.nlm.nih.gov

      Back to overview ↑
    14. 14

      Research publication

      Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)

      pmc.ncbi.nlm.nih.gov

      Back to overview ↑
    15. 15

      Research publication

      Schoenenberger GA, Monnier M (1977) — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    16. 16

      Research publication

      European Journal of Anaesthesiology (2001) — Delta sleep-inducing peptide: editorial review of mechanisms and clinical context (opens in a new tab)

      doi.org

      Back to overview ↑
    17. 17

      Research publication

      Schneider-Helmert D, Schoenenberger GA (1983) — Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    18. 18

      Research publication

      Sudakov KV et al. (2004) — Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    19. 19

      Research publication

      Schneider-Helmert D (1981) — Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    20. 20

      Research publication

      Graf MV, Kastin AJ (1984) — Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    21. 21

      Research publication

      Iyer KS et al. (1988) — Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    22. 22

      Research publication

      Manning MC et al. (2010) — Stability of protein pharmaceuticals: an update. Pharm Res (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    23. 23

      Research publication

      Wang W (2000) — Lyophilization and development of solid protein pharmaceuticals. Int J Pharm (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    24. 24

      Research publication

      Yehuda S, Carasso RL (1988) — DSIP: brain mechanisms and function. Int J Neurosci (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    25. 25

      Research publication

      Khvatova EM et al. (2003) — Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    26. 26

      Public health resource

      NCBI Bookshelf — Medication Administration: Subcutaneous Injections (Open RN Nursing Skills) (opens in a new tab)

      www.ncbi.nlm.nih.gov

      Back to overview ↑